Brief Article
Copyright ©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Orthop. Oct 18, 2013; 4(4): 316-322
Published online Oct 18, 2013. doi: 10.5312/wjo.v4.i4.316
Effect of risedronate on speed of sound in postmenopausal women with osteoporosis
Jun Iwamoto, Tetsuya Takada, Yoshihiro Sato, Hideo Matsumoto
Jun Iwamoto, Hideo Matsumoto, Institute for Integrated Sports Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan
Tetsuya Takada, Department of Internal Medicine, Hiyoshi Medical Clinic, Kanagawa 223-8526, Japan
Yoshihiro Sato, Department of Neurology, Mitate Hospital, Fukuoka 826-0041, Japan
Author contributions: Iwamoto J and Takada T performed the majority of experiments; Sato Y provided vital reagents and analytical tools and were also involved in editing the manuscript; Matsumoto H co-ordinated and provided the collection of all the human material in addition to providing financial support for this work; Iwamoto J designed the study and wrote the manuscript.
Correspondence to: Jun Iwamoto, MD, Institute for Integrated Sports Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. jiwamoto@a8.keio.jp
Telephone: +81-3-3353-1211 Fax: +81-3-3352-9467
Received: January 23, 2013
Revised: July 7, 2013
Accepted: July 12, 2013
Published online: October 18, 2013
Processing time: 277 Days and 20.1 Hours
Abstract

AIM: To examine the effects of treatment with risedronate for 1 year on speed of sound (SOS) of the calcaneus and bone turnover markers in postmenopausal women with osteoporosis.

METHODS: Thirty-eight postmenopausal women with osteoporosis who had been treated with risedronate for > 1 year were enrolled in the study. The SOS and bone turnover markers were monitored during treatment with risedronate for 1 year.

RESULTS: The urinary levels of cross-linked N-terminal telopeptides of type I collagen and serum levels of alkaline phosphatase were significantly decreased at 3 mo (-34.7%) and 12 mo (-21.2%), respectively, compared with the baseline values. The SOS increased modestly, but significantly by 0.65% at 12 mo compared with the baseline value. Treatment with risedronate elicited an increase in the SOS of the calcaneus exceeding the coefficient of variation in vivo (0.27%).

CONCLUSION: The present study confirmed that risedronate suppressed bone turnover and elicited a clinically significant increase in the SOS of the calcaneus in postmenopausal women with osteoporosis.

Keywords: Risedronate; Postmenopausal women; Quantitative ultrasound; Speed of sound; Bone turnover

Core tip: The effects of risedronate treatment on quantitative ultrasound parameters of the calcaneus remain to be established in patients with osteoporosis. The aim of the present clinical practice-based observational study was to examine the effects of treatment with risedronate for 1 year on speed of sound (SOS) of the calcaneus and bone turnover markers in postmenopausal women with osteoporosis. The present study confirmed that risedronate suppressed bone turnover and elicited a clinically significant increase in the SOS of the calcaneus in postmenopausal women with osteoporosis.